Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
NEC 2 ( NCT01229943) Randomized Phase II Study of Everolimus Alone versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours has been permanently closed by the lead group.
About the trial
The official CCTG Facebook page is here!
With so many of our partners and collaborators already using this social media platform, CCTG has officially joined the Cancer Clinical Trials conversation on Facebook. The group's new social media page will focus on sharing lay related stories and information on the subject of cancer clinical trials. With emerging treatments and clinical practice changes it is a great way to keep everyone up-to-date with the latest information in the ever changing world of cancer research.
Each year, at the CCTG Annual Spring Meeting of Participants, we recognize individuals and groups who have made significant contributions to cancer clinical trials research. Winners will be honoured on the evening of Friday, April 27 at the CCTG Recognition Awards Ceremony in Toronto.
There are three intergroup-led trials which have now been deemed permanently closed/terminated by their respective lead group. If you have any questions regarding the trial closure please contact:Christine Bertrim.
Data submission and REB approval for the following trials is no longer required:
CCTG is pleased to announce that the OV.25 trial, A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs) has been centrally activated.
Reminder: Feedback request on Health Canada Guidance GUI-0100 due April 2, 2018
The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has current job openings for two Study Coordinators and a Monitor/Auditor. Please visit our career page to find out more about these roles and how to apply.
